These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19591527)

  • 21. Use of Live Attenuated Influenza Vaccine in Children With Egg Allergy and Asthma.
    Kelso JM
    J Pediatric Infect Dis Soc; 2015 Mar; 4(1):81-2. PubMed ID: 26407364
    [No Abstract]   [Full Text] [Related]  

  • 22. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.
    Silva IR; Kulldorff M
    Biometrics; 2015 Sep; 71(3):851-8. PubMed ID: 26011024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarketing surveillance of adverse drug reactions: patient self-monitoring.
    Fisher S; Bryant SG
    J Am Board Fam Pract; 1992; 5(1):17-25. PubMed ID: 1561919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients' role in reporting adverse drug reactions.
    van Grootheest K; de Jong-van den Berg L
    Expert Opin Drug Saf; 2004 Jul; 3(4):363-8. PubMed ID: 15268652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
    Juhlin K; Ye X; Star K; Norén GN
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug events and near misses: who's counting?
    Wu AW
    Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
    [No Abstract]   [Full Text] [Related]  

  • 29. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison.
    Fletcher AP
    J R Soc Med; 1991 Jun; 84(6):341-4. PubMed ID: 2061900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. European pharmacovigilance: an overview of pharmacovigilance inspections.
    Koster MC; van den Oetelaar AH
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
    [No Abstract]   [Full Text] [Related]  

  • 31. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmarketing surveillance for drug abuse.
    Arfken CL; Cicero TJ
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S97-105. PubMed ID: 12759200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alert systems for post-marketing surveillance of adverse drug reactions.
    Praus M; Schindel F; Fescharek R; Schwarz S
    Stat Med; 1993 Dec; 12(24):2383-93. PubMed ID: 8134741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
    Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
    Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
    [No Abstract]   [Full Text] [Related]  

  • 35. Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.
    French JA
    Epilepsia; 2002 Sep; 43(9):951-5. PubMed ID: 12199719
    [No Abstract]   [Full Text] [Related]  

  • 36. [Drug surveillance: concepts, objectives, and methods].
    Susano RC; Laborinho Fialho L; de Quirós JF
    Acta Med Port; 1992 Dec; 5(11):595-602. PubMed ID: 1293954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
    Moore TJ; Furberg CD
    Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is reporting rate a good predictor of risks associated with drugs?
    Pierfitte C; Bégaud B; Lagnaoui R; Moore ND
    Br J Clin Pharmacol; 1999 Mar; 47(3):329-31. PubMed ID: 10215758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.